Cargando…
Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
INTRODUCTION: Gout is a common and disabling cause of arthritis in middle-aged and elderly populations, with its main predisposing factor being hyperuricemia (serum urate > 6.8 mg/dL). Options for treatment of chronic gout until 2008 were allopurinol, a xanthine oxidase inhibitor, and the group o...
Autores principales: | Gaffo, Angelo L, Saag, Kenneth G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899777/ https://www.ncbi.nlm.nih.gov/pubmed/20694062 |
Ejemplares similares
-
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
por: Gaffo, Angelo L, et al.
Publicado: (2009) -
Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010) -
Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008) -
Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011) -
Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)